References
- Ziel HK, Finkle WD. Increased risk of endo-metrial carcinoma among users of conjugated estrogens. N Engl J Med 1975:293:1167–70
- Smith DC, Prentice R, Thompson DJ, Herrmann WL. Association of exogenous estrogen andendometrial carcinoma. N Engl J Med 1975;293: 1164–7
- Whitehead MI, Townsend PT, Pryse-Davies J, Ryder TA, King RJB. Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. N Engl J Med 1981;305:1599–605
- Pike MC, Peters RK, Cozen W, et al. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 1997;89:1110–16
- Sturdee DW, Ulrich LG, Barlow DH, et al. Endometrial response to sequential and continu-ous combined oestrogen-progestogen replace-ment therapy. Br J Obstet Gynaecol 2000;107: 1392–400
- Beresford SAA, Weiss NF, Voigt LF, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestogentherapy in postmenopausal women. Lancet 1997;349:458–61
- Weiderpass E, Adami HO, Baron JA, et al. Risk of endometrial cancer following estrogen replace-ment with or without progestogens. J Natl Cancer Inst 1999;91:1131–7
- Staland B. Continuous treatment with natural oestrogens and progestogens. A method to avoid endometrial stimulation. Maturitas 1981;3: 145–56
- Wells M, Sturdee DW, Barlow DH, et al. The endometrial response to long-term treatment with continuous combined oestrogen/progesto-gen replacement therapy. Br Med J 2001;in press
- Delmas P, Bjnarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641–7